المؤلفون: Sinha M; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Betts C; Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA., Zhang L; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.; Department of Biostatistics, University of California, San Francisco, California, USA., Griffith MJ; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Solman I; AbbVie, Irvine, California, USA., Chen B; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Liu E; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Tamaki W; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Stultz J; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Marquez J; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Sivagnanam S; Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA., Cheung A; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Pener D; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA., Fahlman A; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA., Taber E; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA., Lerner K; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA., Crocker M; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA., Todd K; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA., Rajagopalan B; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA., Ware C; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Bridge M; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Vo J; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA., Dragomanovich H; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Sudduth-Klinger J; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Vaccaro G; Medical Oncology, Providence Portland Medical Center, Portland, Oregon, USA., Lopez CD; Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA., Tempero M; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA., Coussens LM; Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA., Fong L; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA lawrence.fong@ucsf.edu.; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Jan; Vol. 11 (1).

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Adenocarcinoma*/drug therapy , Antineoplastic Agents*/therapeutic use , Carcinoma, Pancreatic Ductal*/pathology , Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/pathology, Humans ; Gemcitabine ; Programmed Cell Death 1 Receptor/therapeutic use ; Tumor Microenvironment ; Tyrosine Kinase Inhibitors ; Pancreatic Neoplasms

المؤلفون: Overman M; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA moverman@mdanderson.org., Javle M; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Davis RE; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Vats P; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan, USA., Kumar-Sinha C; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan, USA., Xiao L; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Mettu NB; Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, North Carolina, USA., Parra ER; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Benson AB; Department of Medicine, Hematology Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USA., Lopez CD; Department of Oncology, School of Medicine, Oregon Health and Science University Foundation, Portland, Oregon, USA., Munugalavadla V; Acerta Pharma LLC, Redwood City, California, USA., Patel P; Acerta Pharma LLC, Redwood City, California, USA., Tao L; Acerta Pharma LLC, Redwood City, California, USA., Neelapu S; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Maitra A; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Feb; Vol. 8 (1).

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Agammaglobulinaemia Tyrosine Kinase/*antagonists & inhibitors , Antibodies, Monoclonal, Humanized/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Benzamides/*administration & dosage , Carcinoma, Pancreatic Ductal/*drug therapy , Pancreatic Neoplasms/*drug therapy , Pyrazines/*administration & dosage, Administration, Intravenous ; Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Benzamides/adverse effects ; Carcinoma, Pancreatic Ductal/diagnosis ; Carcinoma, Pancreatic Ductal/immunology ; Carcinoma, Pancreatic Ductal/mortality ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; Myeloid-Derived Suppressor Cells/drug effects ; Myeloid-Derived Suppressor Cells/immunology ; Pancreatic Neoplasms/diagnosis ; Pancreatic Neoplasms/immunology ; Pancreatic Neoplasms/mortality ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Progression-Free Survival ; Proof of Concept Study ; Pyrazines/adverse effects ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/immunology